Category: Publications

12

Nov2021

Final Analysis from AMPECT, an Open-Label Phase 2 Registration Trial of nab-Sirolimus for Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)

0  
November 12, 2021

12

Oct2021

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

0  
October 12, 2021

07

Oct2021

nab-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and TSC2 null liver cancer (SNU398) xenografts

0  
October 7, 2021

04

Jun2021

Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

0  
June 4, 2021

20

Nov2020

Long-Term Follow-Up from AMPECT, an Open-Label Phase 2 Registration Trial of nab-Sirolimus for Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)

0  
November 20, 2020

20

Jun2020

Long-term follow-up for duration of response (DOR) after weekly nab-sirolimus (ABI-009) in patients with advanced malignant perivascular epitlhelioid cell tumors (PEComa): Results from a registrational open-label phase 2 trial, AMPECT

0  
June 20, 2020

20

Jun2020

Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss

0  
June 20, 2020

24

Nov2019

A phase 2 trial with ABI-009 (nab-sirolimus) as single-agent and combinations in recurrent high-grade glioma (rHGG) and in newly diagnosed glioblastoma (ndGBM)

0  
November 24, 2019

20

Nov2019

Mutational and Biomarker Correlative Analysis of mTOR Pathway Aberrations in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa) Treated With nab-Sirolimus: Results From AMPECT, an Open-Label Phase 2 Registration Trial

0  
November 20, 2019

14

Nov2019

Weekly nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Results From AMPECT, An Open-Label Phase 2 Registration Trial With Independent Radiology Review

0  
November 14, 2019